経皮薬物送達（Transdermal Drug Delivery）市場及びパイプラインインサイト...市場調査レポートについてご紹介

1. Introduction to Transdermal Drug Delivery

2. Transdermal Drug Delivery Mechanism
2.1 Mechanisms of Transdermal Drug Delivery
2.2 Types of Transdermal Patch

3. Why Need For Transdermal Drug Delivery?

4. Transdermal Drug Delivery Market Outlook
4.1 Market Overview
4.2 Clinical Pipeline Analysis

5. Transdermal Drug Delivery Market Dynamics
5.1 Favorable Market Drivers
5.2 Key Issues to be Discussed

6. Future of Transdermal Drug Delivery Market

7. Guidelines/Regulations for Transdermal Drug Delivery
7.1 EMA Guideline for Quality of Transdermal Patches
7.2 FDA Guidelines for Residual Drug in Transdermal & Related Drug Delivery Systems

8. Transdermal Drug Delivery Clinical Trial Insight by Phase, Country & Target Indications
8.1 Unknown Phase
8.2 Research
8.3 Preclinical
8.4 Clinical
8.5 Phase I
8.6 Phase I/II
8.7 Phase II
8.8 Phase III
8.9 Preregistration
8.10 Registered

9. Marketed Transdermal Drug Profiles

10. Suspended & Discontinued Transdermal Drug Profiles
10.1 No Development Reported
10.2 Discontinued
10.3 Market Withdrawal
10.4 Suspended

11. Competitive Landscape
11.1 Acrux
11.2 ANI Pharmaceuticals
11.3 Antares Pharma
11.4 Bayer HealthCare Pharmaceuticals
11.5 Dermatrends Inc.
11.6 Durect Corporation
11.7 Nuvo Research
11.8 Novartis
11.9 Phosphagenics
11.10 Zosano Pharma

Figure 1-1: Drug Delivery Methods
Figure 2-1: Transdermal Drug Delivery Mechanism
Figure 4-1: Composition of Drug Delivery Market
Figure 4-2: Global Transdermal Drug Delivery Market (US$ Billion), 2013-2018
Figure 4-3: Regional Market for Transdermal Drug Delivery
Figure 4-4: Transdermal Drugs in Clinical Trial by Phase (%), 2014
Figure 4-5: Number of Transdermal Drugs in Clinical Trial by Phase, 2014
Figure 4-6: Inactive Transdermal Drugs in Clinical Trial by Phase (%), 2014
Figure 4-7: Number of Inactive Transdermal Drugs in Clinical Trial by Phase, 2014
Figure 4-8: No Development in Transdermal Drugs in Clinical Trial by Phase (%), 2014
Figure 4-9: Number of No Development in Transdermal Drugs in Clinical Trial by Phase, 2014
Figure 4-10: Discontinued Transdermal Drugs in Clinical Trial by Phase (%), 2014
Figure 4-11: Number of Discontinued Transdermal Drugs in Clinical Trial by Phase, 2014
Figure 4-12: Suspended Transdermal Drugs in Clinical Trial by Phase (%), 2014
Figure 4-13: Number of Suspended Transdermal Drugs in Clinical Trial by Phase, 2014
Figure 6-1: Developments in Transdermal Drug Delivery
Figure 11-1: Acrux Clinical Pipeline
Figure 11-2: Antares Pharma Clinical Pipeline
Figure 11-3: DURECT Corporation Clinical Pipeline
Figure 11-4: Phosphagenics Clinical Pipeline
Figure 11-5: Zosano Pharma Clinical Pipeline